Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
80 participants
INTERVENTIONAL
2013-03-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Artemether/Lumefantrine and Vivax Malaria
NCT01625871
Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study
NCT06472258
Phase II Artesunate Study in Severe Malaria
NCT00522132
Safety and Efficacy Study of IV Artesunate to Treat Malaria
NCT00298610
Very Severe Malaria Treated by Intravenous Artesunate
NCT04516317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
artesunate
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
artesunate
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
Quinine
quinine infusion 80 mg/kg every 8 hours till the patient can take orally
quinine
quinine infusion 80 mg/kg every 8 hours
artesunate
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
Quinine
quinine infusion 80 mg/kg every 8 hours till the patient can take orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
artesunate
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
Quinine
quinine infusion 80 mg/kg every 8 hours till the patient can take orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kassala, Sudan
OTHER
Kassala
UNKNOWN
Sudan
UNKNOWN
University of Khartoum
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ishag Adam
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kassala
Kassala, Kassala, Sudan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Eltahir HG, Omer AA, Mohamed AA, Adam I. Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2010 Oct;104(10):684-6. doi: 10.1016/j.trstmh.2010.05.009. Epub 2010 Jun 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
artesunate and malaria
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.